Jan Östergren

33.8k total citations · 9 hit papers
140 papers, 19.7k citations indexed

About

Jan Östergren is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Physiology. According to data from OpenAlex, Jan Östergren has authored 140 papers receiving a total of 19.7k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Cardiology and Cardiovascular Medicine, 38 papers in Surgery and 21 papers in Physiology. Recurrent topics in Jan Östergren's work include Blood Pressure and Hypertension Studies (40 papers), Heart Failure Treatment and Management (33 papers) and Cardiovascular Function and Risk Factors (24 papers). Jan Östergren is often cited by papers focused on Blood Pressure and Hypertension Studies (40 papers), Heart Failure Treatment and Management (33 papers) and Cardiovascular Function and Risk Factors (24 papers). Jan Östergren collaborates with scholars based in Sweden, United Kingdom and United States. Jan Östergren's co-authors include Salim Yusuf, John J.V. McMurray, Karl Swedberg, Eric L. Michelson, Bertil Olofsson, Marc A. Pfeffer, Christopher B. Granger, Peter Held, Eoin OʼBrien and Jesper Mehlsen and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Jan Östergren

139 papers receiving 18.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

2003 2.7k citations Hans Wedel, Gareth Beevers et al. profile →
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

2003 2.0k citations Salim Yusuf, Marc A. Pfeffer et al. profile →
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

2005 1.9k citations Hans Wedel, Mark J. Caulfield et al. profile →
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

2003 1.8k citations John J.V. McMurray, Jan Östergren et al. profile →
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

2003 1.3k citations Marc A. Pfeffer, Karl Swedberg et al. profile →
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

2003 1.1k citations Christopher B. Granger, John J.V. McMurray et al. profile →
CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL

2003 794 citations John J.V. McMurray, Jan Östergren et al. profile →
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure

2006 733 citations Marc A. Pfeffer, Karl Swedberg et al. profile →
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

2008 503 citations Mark C. Petrie, Jan Östergren et al. profile →

Peers

Countries citing papers authored by Jan Östergren

Since Specialization

Citations

This map shows the geographic impact of Jan Östergren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Östergren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Östergren more than expected).

Fields of papers citing papers by Jan Östergren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Östergren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Östergren. The network helps show where Jan Östergren may publish in the future.

Co-authorship network of co-authors of Jan Östergren

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Östergren. A scholar is included among the top collaborators of Jan Östergren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Östergren. Jan Östergren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease—A randomized controlled trial 2020 ·SHILAP Revista de lepidopterología ·(unknown), Per Svensson, Cecilia Linde, Jan Östergren	6
2	Retinopathy of Prematurity Is Associated with Increased Systolic Blood Pressure in Adults Who Were Born Preterm 2017 ·Neonatology ·Anna Kistner, Lena Jacobson, Jan Östergren, Ann Hellström	4
3	Corrigendum to ‘Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved’ [ Eur J Heart Fail 2014;16:33–40] 2014 ·European Journal of Heart Failure ·Jennifer K. Rogers, Stuart Pocock, John J.V. McMurray, Christopher B. Granger, Eric L. Michelson, Jan Östergren, Marc A. Pfeffer, Scott D. Solomon, Karl Swedberg, Salim Yusuf	3
4	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary 2014 ·Diabetes and Vascular Disease Research ·(unknown), (unknown), Lars Rydén, Peter J. Grant, Stefan D. Anker, Christian Berne, Francesco Cosentino, Nicolas Danchin, Christi Deaton, Javier Escaned, Hans‐Peter Hammes, Heikki Huikuri, Michel Marre, Nikolaus Marx, Linda Mellbin, Jan Östergren, Carlo Patrono, Petar Seferovic, Miguel Sousa‐Uva, Marja‐Riitta Taskinen, Michał Tendera, (unknown)	162
5	Does individual learning styles influence the choice to use a web-based ECG learning programme in a blended learning setting? 2012 ·BMC Medical Education ·Mikael Nilsson, Jan Östergren, Uno Fors, Anette Rickenlund, L. Jorfeldt, Kenneth Caidahl, Gunilla Bolinder	24
6	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program 2011 ·American Heart Journal ·Cono Ariti, John G.F. Cleland, Stuart Pocock, Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger, John J.V. McMurray, Eric L. Michelson, Jan Östergren, Salim Yusuf	141
7	Baseline Characteristics and Outcomes of Patients with Heart Failure Receiving Bronchodilators in the CHARM Programme 2010 ·European Journal of Heart Failure ·Nathaniel M. Hawkins, Duolao Wang, Mark C. Petrie, Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger, Salim Yusuf, Scott D. Solomon, Jan Östergren, Eric L. Michelson, Stuart Pocock, Aldo P. Maggioni, John J.V. McMurray	55
8	Adherence to Medication According to Sex and Age in the CHARM Programme 2009 ·European Journal of Heart Failure ·Bradi B. Granger, Inger Ekman, Christopher B. Granger, Jan Östergren, Bertil Olofsson, Eric L. Michelson, John J.V. McMurray, Salim Yusuf, Marc A. Pfeffer, Karl Swedberg	108
9	Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program 2008 ·Journal of the American College of Cardiology ·Peter Meredith, Jan Östergren, Inder S. Anand, Margareta Puu, Scott D. Solomon, Eric L. Michelson, Bertil Olofsson, Christopher B. Granger, Salim Yusuf, Karl Swedberg, Marc A. Pfeffer, John J.V. McMurray	33
10	Prevalence and Prognostic Impact of Bundle Branch Block in Patients with Heart Failure: Evidence from the CHARM Programme 2007 ·European Journal of Heart Failure ·Nathaniel M. Hawkins, Duolao Wang, John J.V. McMurray, Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger, Salim Yusuf, Stuart Pocock, Jan Östergren, Eric L. Michelson, Francis G. Dunn	45
11	Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence 2007 ·Journal of the American College of Cardiology ·Hans Persson, Eva Lonn, Magnus Edner, Lawrence Baruch, Chim C. Lang, John J. Morton, Jan Östergren, Robert S. McKelvie	214
12	The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb (ASCOT-BPLA): effects in patients with type 2 diabetes 2006 ·Diabetologia ·Jan Östergren, (unknown), N. Poulter, Björn Dahlöf, Hans Wedel, Gareth Beevers, Mark J. Caulfield, (unknown), SE Kjeldsen, Arni Kristinsson, GT McInnes, Jesper Mehlsen, Markku M. Nieminen, E T O'Brien	6
13	Patient Perception of the Effect of Treatment with Candesartan in Heart Failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme 2005 ·European Journal of Heart Failure ·Eileen O’Meara, Eldrin F. Lewis, C. B. Granger, Mark E. Dunlap, Robert S. McKelvie, Jeffrey L. Probstfield, James B. Young, Eric L. Michelson, Jan Östergren, Jonas Carlsson, Bertil Olofsson, John J.V. McMurray, Salim Yusuf, Karl Swedberg, Marc A. Pfeffer	21
14	1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study 2004 ·Journal of the American College of Cardiology ·Scott D. Solomon, Bertil Olofsson, Peter Finn, Hicham Skali, Leonardo Antônio Mamede Zornoff, Satish Kenchaiah, Nagesh S. Anavekar, Jan Östergren, Eric L. Michelson, (unknown), (unknown), Salim Yusuf, John J.V. McMurray, C. B. Granger, Marc A. Pfeffer	2
15	WHAT IS THE RELEVANCE OF THE HOPE STUDY IN GENERAL PRACTICE? 2001 ·International Journal of Clinical Practice ·J. W. Kennedy, Mogensen Ce, Susan Ball, (unknown), Commerford Pj, (unknown), BM Fisher, (unknown), R. Nosadini, Anna Novials, Jan Östergren, (unknown), (unknown), (unknown), Jochen Senges, Roberto Trevisan	2
16	Episodes of ST‐segment depression is related to changes in ambulatory blood pressure and heart rate in intermittent claudication 2001 ·Journal of Internal Medicine ·Per Svensson, (unknown), Jan Östergren	10
17	Adrenaline Responsiveness in Mild Hypertension: No Evidence for Altered β-Adrenoceptor Sensitivity 1998 ·Journal of Cardiovascular Pharmacology ·Thomas Kahan, Paul Hjemdahl, Kaj Lindvall, Jan Östergren, Ulf dé Fairé	5
18	Effect of Amlodipine Versus Felodipine Extended Release on 24-Hour Ambulatory Blood Pressure in Hypertension 1998 ·American Journal of Hypertension ·Jan Östergren, (unknown), Ulf Brodin, (unknown), K. Peter Öhman, (unknown)	14
19	Quality of Life in Hypertensive Patients Treated with Either Carvedilol or Enalapril 1996 ·Blood Pressure ·Jan Östergren, Liv Storstein, B. E. Karlberg, Gösta Tibblin	21
20	MICROVASCULAR REACTIVITY IN LONG DURATION TYPE-1 DIABETICS WITHOUT MICROVASCULAR COMPLICATIONS 1984 ·UCL Discovery (University College London) ·(unknown), (unknown), Jan Östergren, B Fagrell	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact